GGrantIndex
← Search

Flow Cytometry Shared Resource

$138,432P30FY2023CANIH

Albert Einstein College Of Medicine, Bronx NY

Investigators

Linked publications, trials & patents

Paper 39499645Paper 39392861Paper 39378878Paper 39332920Paper 39259591Paper 39207105Paper 39193906Paper 39127153Paper 39081315Paper 39028768Paper 39025270Paper 38902475Paper 38898085Paper 38896451Paper 38863869Paper 38778498Paper 38753503Paper 38717519Paper 38700353Paper 38699331Paper 38679747Paper 38657656Paper 38645169Paper 38643166Paper 38608634Paper 38597673Paper 38571760Paper 38565851Paper 38559037Paper 38477945Paper 38463959Paper 38458178Paper 38436133Paper 38405931Paper 38402617Paper 38400039Paper 38387080Paper 38352476Paper 38334805Trial NCT05016622Trial NCT04514484Trial NCT04401670Trial NCT03648983Trial NCT02774291Trial NCT02649569Trial NCT02578888Trial NCT02575872Trial NCT02527304Trial NCT02507076Trial NCT02382419Trial NCT02277561Trial NCT02112552Trial NCT02073968Trial NCT02038153Trial NCT02009436Trial NCT01958580Trial NCT01939210Trial NCT01899326Trial NCT01899261Trial NCT01897454Trial NCT01897441Trial NCT01857271Trial NCT01772420Trial NCT01697293Trial NCT01695941Trial NCT01605032Trial NCT01408160Trial NCT01367301Trial NCT01351909Trial NCT01319539Trial NCT01231906Trial NCT01145430Trial NCT01142401Trial NCT01061606Trial NCT01041027Trial NCT01001910Trial NCT00950365Trial NCT00470301Trial NCT00450944Trial NCT00437034Trial NCT00392353Trial NCT00324740Trial NCT00182767Trial NCT00179348Trial NCT00121251Trial NCT00096317Trial NCT00066638Trial NCT00057863Trial NCT00055692Trial NCT00030706Trial NCT00019474Trial NCT00004864Trial NCT00004863Trial NCT00003867Trial NCT00002461Patent 9671391Patent 7709613Patent 6821725Patent 6013468Patent 5876979

Abstract

Program Director/Principal Investigator (Last, First, Middle): Chu, Edward FLOW CYTOMETRY SHARED RESOURCE - PROJECT SUMMARY/ABSTRACT The overall goal of the Flow Cytometry Shared Resource (FCSR) is to provide a broad array of advanced cell analysis and isolation resources for a wide range of cancer-relevant studies carried out by basic and translational scientists in the MECC. As a central component of its mission, the FCSR provides access to instrumentation and expertise for analytical flow cytometry and fluorescence activated cell sorting. These resources are critical for a large cohort of MECC scientists who use these technologies on a regular basis in their studies to explore the biology of cancer and develop new therapeutics. Analytical flow cytometers housed in the FCSR include the most advanced multispectral analyzers currently available (Cytek Aurora), with capabilities for rapid analysis of >25 parameters per cell. A range of cell sorters are also provided, including cuvette type (FACSAria) and jet-in- air type (MoFlow and Astrios) high speed sorters. FCSR has also recently acquired the most cutting edge, newly developed multispectral cell sorter (ThermoFisher Bigfoot), which elevates the speed, accuracy and complexity of cell sorting capabilities to unprecedented levels. In addition to its state-of-the-art core technologies in flow cytometry, the FCSR has also expanded to incorporate several new related and complementary technology platforms for immune monitoring of cancers in human subjects and animal models. These include the recent acquisition of a multi-channel fluorescence slide scanning system (VectraPolaris), and equipment for gene expression profiling at single cell and microscopic tissue levels (NanoString). FCSR provides technical expertise and training to guide MECC investigators at all levels in the application of basic and advanced flow cytometry and its other supported technologies. Services and training are supported by a full-time staff consisting of three highly experienced research faculty level operations directors who carry out advanced technical procedures, supervise training activities and manage the daily operations. There are also four experienced and highly trained technicians who support equipment operation and maintenance. Ongoing review of new developments in areas relevant to the FCSR by the senior faculty scientific director and faculty advisory group of the facility assures that MECC investigators have access to the most advanced current and newly emerging technologies for cell analysis and isolation. FCSR also organizes and supports seminars and demonstrations of new technologies to ensure that MECC investigators are well informed about newly emerging applications of FACS and other related technologies that can enhance their research. The technologies provided by FCSR are essential to the research activities of MECC investigators and cannot be outsourced or obtained at other sites in any practical or cost- effective way. FCSR serves as a critical component of MECC Shared Resources, and is a major pillar of support for a wide range of cancer-focused basic and translational research. OMB No. 0925-0001/0002 (Rev. 03/2020 Approved Through 02/28/2023) Page

View original record on NIH RePORTER →